Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Pairing tirzepatide (Zepbound) with ixekizumab (Taltz) significantly improves psoriasis and psoriatic arthritis outcomes at the 1-year mark. Phase 3b trial data show the combo far outperformed ixekizumab alone on skin clearance and joint improvement — plus meaningful weight loss. Eli Lilly's TOGETHER-PsO and TOGETHER-PsA trials are reshaping how clinicians think about treating psoriatic disease in patients with obesity.
Combining a GLP-1 drug with a biologic is changing the game for psoriatic disease. One-year results from Eli Lilly's phase 3b TOGETHER-PsO and TOGETHER-PsA trials show that pairing tirzepatide (Zepbound) with ixekizumab (Taltz) dramatically outperforms ixekizumab alone in adults with moderate-to-severe psoriasis or psoriatic arthritis who also have overweight or obesity.
The trials enrolled adults who had at least one additional weight-related comorbidity alongside their skin or joint disease. Both studies used a composite primary endpoint — requiring both disease improvement and meaningful weight loss — setting a high bar that the combination therapy cleared by a wide margin. Beyond skin and joint outcomes, the combo also improved systemic inflammation markers and cardiometabolic risk factors including blood pressure, cholesterol, triglycerides, and HbA1c.
By the Numbers:
Why it matters: Psoriasis and psoriatic arthritis frequently co-exist with obesity and elevated cardiovascular risk. These results suggest that treating the immune and metabolic components together — rather than skin disease in isolation — could become a new standard of care, offering patients both clearer skin and improved overall health.
